Vizsgálati helyszín
Les Hopitaux Nord-Ouest
Villefranche Sur Saone Cedex, 69655, FranciaországMég nincs intézményhez kötve
- 22futó vizsgálat
- 4lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 27 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis16 vizsgálat
- 2. fázis9 vizsgálat
- 2/3. fázis1 vizsgálat
- 4. fázis1 vizsgálat
- Állapot
- Toboroz10 vizsgálat
- Fut, nem toboroz7 vizsgálat
- Még nem toboroz5 vizsgálat
- Lezárult4 vizsgálat
- Felfüggesztve1 vizsgálat
- Fő szponzor
- AstraZeneca4 vizsgálat
- Bristol-Myers Squibb2 vizsgálat
- Intergroupe Francophone de Cancerologie Thoracique2 vizsgálat
- Mirati Therapeutics Inc.2 vizsgálat
- UNICANCER2 vizsgálat
- és még 15
Futó vizsgálatok
Még nem toboroz
A trial to learn how well Dato-DXd works and how safe it is with other anticancer drugs in adults with TROP2 NMR-positive non-small cell lung cancer
2025-524836-21-00· 2. fázis· AstraZeneca AB· Forrás
Toboroz
Efficacy of prophylactic levetiracetam for improving functional outcome in the acute phase of intracerebral haemorrhage:
a randomised, double-blind, placebo-controlled, phase 3 trial
PEACH 2
2024-515663-59-00· 3. fázis· Hospices Civils De Lyon· Forrás
Még nem toboroz
Tenecteplase for the treatment of acute stroke in the late time window before inter-hospital transfer for thrombectomy: a randomized controlled trial
2026-525280-40-00· 3. fázis· Fondation A De Rothschild· Forrás
Toboroz
Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer
NCT07473128· 3. fázis· Pharmacosmos A/S· Forrás
Még nem toboroz
Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer
NCT07151586· 2. fázis· UNICANCER· Forrás
Toboroz
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
NCT07566052· 3. fázis· Astellas Pharma Global Development, Inc.· Forrás
Toboroz
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
NCT07365319· 2/3. fázis· Eikon Therapeutics· Forrás
Toboroz
Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of Exacerbations
NCT07566195· 3. fázis· AstraZeneca· Forrás
Toboroz
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
NCT07472517· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
NCT07361510· 3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
NCT06745908· 3. fázis· ImmunityBio, Inc.· Forrás
Toboroz
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
NCT06646276· 3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC
NCT06552234· 2. fázis· Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer· Forrás
Toboroz
FIRST-NEC - A multicenter phase II study evaluating the efficacy and safety of the combination of durvalumab (MEDI 4736) with etoposide and platinum as first line treatment in patients with large-cell neuroendocrine carcinomas (LCNECs) of the lung.
2023-506590-35-00· 2. fázis· Centre Leon Berard· Forrás
Fut, nem toboroz
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774· 3. fázis· Amgen· Forrás
Toboroz
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
NCT06170788· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax
NCT05617963· 2. fázis· UNICANCER· Forrás
Fut, nem toboroz
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
NCT05687266· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)
NCT05200481· 2. fázis· Intergroupe Francophone de Cancerologie Thoracique· Forrás
Toboroz
Short Treatment with Omalizumab for Severe Asthma
NCT04763447· 4. fázis· Assistance Publique - Hôpitaux de Paris· Forrás
Fut, nem toboroz
ENCOrafenib With Binimetinib in bRAF NSCLC
NCT04526782· 2. fázis· Intergroupe Francophone de Cancerologie Thoracique· Forrás
Fut, nem toboroz
Rituximab from the first episode of Minimal Change Nephrotic Syndrome for preventing relapse risk in adult patients
NCT03970577· 2. fázis· Assistance Publique Hopitaux De Paris· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek